Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...

The company will present these findings and data from previous studies at the upcoming Pain Therapeutics Summit. The company is preparing to submit an Investigational New Drug (IND) application by ...

For all the known benefits CBD offers, it’s unclear how well it can relieve nerve pain ... effects or make certain medications ineffective. CBD oil is relatively new as a treatment for many ...

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

A wearable, app-controlled wireless device that stimulates nerves in the legs and feet may help individuals with cancer who suffer from burning and shooting pain and cramping in their lower limbs ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Research shows this side effect can be more severe and more common in Black breast cancer patients, causing doctors to dial back their life-saving medication ... not have to receive the neuropathy, ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...